About us
Pricing
Contact
Subscribe
Journals
Articles
Research Areas
Publishers
Trends
World Map
Compare
Site Map
R
Rodolfo F. Perini
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID https://orcid.org/0009-0002-4400-5260
h-index
—
Publications
—
Citations
—
i10-index
—
Impact (2-yr)
—
Top Publications
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
The Lancet Oncology
2017
1,329 citations
Rodolfo F. Perini · Scinovex
